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Supraventricular tachycardia: back to basics
In The Lancet, Andrew Appelboam and colleagues1 
present the ﬁ ndings of a simple but clinically relevant 
investigation of a safe and non-invasive treatment 
for patients with stable supraventricular tachycardia 
who present to emergency departments. This topic 
is important because patients with supraventricular 
tachycardia are common, often recurrent, emergency 
department attenders, and can require critical care 
interventions. A Cochrane review2 did not ﬁ nd suﬃ  cient 
evidence to support or refute the eﬀ ectiveness of the 
Valsalva manoeuvre to end supraventricular tachycardia.
The study by Appelboam and colleagues1 adds 
signiﬁ cantly to the evidence base for the Valsalva 
manoeuvre. 214 patients were randomly assigned to each 
of two groups, treated with a standard semi-recumbent 
Valsalva manoeuvre or a modiﬁ ed manoeuvre (done 
semi-recumbent with supine repositioning and passive 
leg raise after the Valsalva strain). In terms of the 
primary endpoint, return to sinus rhythm 1 min after the 
intervention, 93 (43%) of 214 participants assigned to 
the modiﬁ ed Valsalva manoeuvre group achieved sinus 
rhythm, compared with 37 (17%) of 214 participants in 
the standard Valsalva manoeuvre group (adjusted odds 
ratio 3·7 [95% CI 2·3–5·8]).
Whenever a new potential standard of care is proposed, 
its risks and beneﬁ ts must be considered. The principle 
of never causing harm to patients is enshrined in the 
Hippocratic oath and is a concept increasingly challenged 
by both modern medicine and societal expectations. 
Although more observations are necessary, the ease and 
safety of the modiﬁ ed Valsalva manoeuvre described by 
Appelboam and co-workers1 suggest that this procedure 
could rapidly be incorporated into standard practice.
The Valsalva manoeuvre is well known, but the technique 
used is variable. By using a standardised implementation 
of 40 mm Hg pressure, followed by supine positioning and 
leg elevation, Appelboam and colleagues1 have created 
a minimally invasive, straightforward procedure with 
which almost 50% of patients can achieve cardioversion. 
Blowing into a 10 mL syringe with suﬃ  cient force to 
move the plunger, as described by Smith and Boyle,3 
will probably generate a similar pressure to that used by 
Appelboam and colleagues.
There is no suggestion that the modiﬁ ed Valsalva 
manoeuvre will not be as eﬀ ective outside hospital, 
although Appelboam and co-workers1 did not test this 
speciﬁ cally. Thus, the technique might enable patients to 
avoid admission to hospital. Even when unsuccessful, it 
is unlikely to cause harm or signiﬁ cantly delay transfer to 
a medical facility. In fact, when the Valsalva manoeuvre 
fails, continued symptoms would justify presentation 
to an emergency department for more aggressive 
interventions, as occurs now in most cases. Although 
the accompanying study is too small to be absolutely 
certain of safety, there is no sign of increased risk of 
adverse events from attempting the modiﬁ ed Valsalva 
manoeuvre (there were no serious adverse events), and, 
because the attempt at self-cardioversion would take 
less than 30 s, it is unlikely to signiﬁ cantly delay seeking 
a higher level of care.
Compared with the other options available to treat 
supraventricular tachycardia,4 the advantage of the 
Valsalva manoeuvre, regardless of being at home or in 
hospital, is that it helps to identify a population in whom 
aggressive treatment is justiﬁ ed. Adenosine is often 
used,4 but it is expensive and unpleasant for the patient, 
and most clinicians would prefer to avoid it if possible. 
Other treatments such as calcium channel blockers, 
β blockers, or even electrical cardioversion, have a small 
but important rate of adverse events.4 The modiﬁ ed 
Valsalva manoeuvre seems to be easy, inexpensive, 
non-invasive, and reproducible (162 diﬀ erent clinicians 
did the manoeuvre in Appelboam and colleagues’ 
study1); thus, an attempt by all patients before invasive 
treatment seems a reasonable part of standard of care. 
*Martin Than, William F Peacock
Christchurch Hospital, Christchurch, Canterbury 8011, New Zealand 
(MT); and Baylor Medical College, Houston, TX, USA (WFP)
martinthan@xtra.co.nz 
We declare no competing interests. 
Copyright © Than et al. Open Access article distributed under the terms of CC BY.
1 Appelboam A, Reuben A, Mann C, et al, on behalf of the REVERT trial 
collaborators. Postural modiﬁ cation to the standard Valsalva manoeuvre 
for emergency treatment of supraventricular tachycardias (REVERT): 
a randomised controlled trial. Lancet 2015; published online Aug 25. 
http://dx.doi.org/10.1016/S0140-6736(15)61485-4.
2 Smith GD, Fry MM, Taylor D, Morgans A, Cantwell K. Eﬀ ectiveness of the 
Valsalva manoeuvre for reversion of supraventricular tachycardia. 
Cochrane Database Syst Rev 2015; 2: CD009502.
3 Smith G, Boyle M. The 10ml syringe is useful in generating the 
recommended standard of 40mmHg intrathoracic pressure for the Valsalva 
manoeuvre. Emerg Med Australas 2009; 21: 449–54.
4 Link MS. Evaluation and initial treatment of supraventricular tachycardia. 
N Engl J Med 2012; 367: 1438–48.
Published Online
August 25, 2015
http://dx.doi.org/10.1016/
S0140-6736(15)61514-8
See Articles page 1747
Dr
 P
 M
ar
az
zi/
Sc
ie
nc
e 
Ph
ot
o 
Li
br
ar
y 
